171 related articles for article (PubMed ID: 21220498)
1. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Marampon F; Gravina GL; Di Rocco A; Bonfili P; Di Staso M; Fardella C; Polidoro L; Ciccarelli C; Festuccia C; Popov VM; Pestell RG; Tombolini V; Zani BM
Mol Cancer Ther; 2011 Jan; 10(1):159-68. PubMed ID: 21220498
[TBL] [Abstract][Full Text] [Related]
2. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
[TBL] [Abstract][Full Text] [Related]
3. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
[TBL] [Abstract][Full Text] [Related]
4. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
6. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay.
Marampon F; Gravina GL; Zani BM; Popov VM; Fratticci A; Cerasani M; Di Genova D; Mancini M; Ciccarelli C; Ficorella C; Di Cesare E; Festuccia C
Int J Oncol; 2014 Jun; 44(6):2121-31. PubMed ID: 24676782
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
9. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
10. Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases.
De Luna N; Suarez-Calvet X; Garicano M; Fernandez-Simon E; Rojas-García R; Diaz-Manera J; Querol L; Illa I; Gallardo E
J Neuropathol Exp Neurol; 2018 Oct; 77(10):964-972. PubMed ID: 30184235
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
Fukazawa H; Noguchi K; Murakami Y; Uehara Y
Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
[TBL] [Abstract][Full Text] [Related]
12. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
Schmidt CM; Wang Y; Wiesenauer C
J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712
[TBL] [Abstract][Full Text] [Related]
13. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
17. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
[TBL] [Abstract][Full Text] [Related]
18. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
20. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T
Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
